# Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies

> **NCT02214160** · PHASE2 · COMPLETED · sponsor: **Ultragenyx Pharmaceutical Inc** · enrollment: 94 (actual)

## Conditions studied

- Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency
- Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency
- Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency
- Trifunctional Protein (TFP) Deficiency
- Carnitine-acylcarnitine Translocase (CACT) Deficiency

## Interventions

- **DRUG:** UX007

## Key facts

- **NCT ID:** NCT02214160
- **Lead sponsor:** Ultragenyx Pharmaceutical Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-09
- **Primary completion:** 2020-12-03
- **Final completion:** 2020-12-03
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02214160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02214160, "Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02214160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*